Clinical Trial Detail

NCT ID NCT02906371
Title Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Pennsylvania
Indications

acute lymphoblastic leukemia

lymphoblastic lymphoma

Therapies

Tocilizumab

Age Groups: child adult

No variant requirements are available.